129 related articles for article (PubMed ID: 36946146)
21. Clinical and economic impact of pharmacists' intervention in a large volume chemotherapy preparation unit.
Han JM; Ah YM; Suh SY; Jung SH; Hahn HJ; Im SA; Lee JY
Int J Clin Pharm; 2016 Oct; 38(5):1124-32. PubMed ID: 27365091
[TBL] [Abstract][Full Text] [Related]
22. Quality assessment and cost saving of renal dosing recommendation by clinical pharmacists at medical wards in Thailand.
Sukkha S; Rattanavipanon W; Chamroenwit B; Sanganurak M; Nathisuwan S; Chaikledkaew U; Kongwatcharapong J
Int J Clin Pharm; 2020 Apr; 42(2):610-616. PubMed ID: 32221826
[TBL] [Abstract][Full Text] [Related]
23. Impact of pharmacist interventions on clinical outcome and cost avoidance in a university teaching hospital.
Jourdan JP; Muzard A; Goyer I; Ollivier Y; Oulkhouir Y; Henri P; Parienti JJ; Breuil C
Int J Clin Pharm; 2018 Dec; 40(6):1474-1481. PubMed ID: 30367375
[TBL] [Abstract][Full Text] [Related]
24. Implementation and pharmacoeconomic analysis of a clinical staff pharmacist practice model.
Nesbit TW; Shermock KM; Bobek MB; Capozzi DL; Flores PA; Leonard MC; Long JK; Militello MA; White DA; Barone LD; Goldman MP; Kvancz DA
Am J Health Syst Pharm; 2001 May; 58(9):784-90. PubMed ID: 11351918
[TBL] [Abstract][Full Text] [Related]
25. Economic effects of clinical pharmacy interventions: a literature review.
De Rijdt T; Willems L; Simoens S
Am J Health Syst Pharm; 2008 Jun; 65(12):1161-72. PubMed ID: 18541687
[TBL] [Abstract][Full Text] [Related]
26. Clinical and economic impact of clinical pharmacist intervention in a hematology unit.
Chen PZ; Wu CC; Huang CF
J Oncol Pharm Pract; 2020 Jun; 26(4):866-872. PubMed ID: 31566112
[TBL] [Abstract][Full Text] [Related]
27. Clinical, Economic, and Organizational Impact of the Clinical Pharmacist in an Orthopedic and Trauma Surgery Department.
Renaudin P; Coste A; Audurier Y; Berbis J; Canovas F; Jalabert A; Castet-Nicolas A; Mercier G; Villiet M; Dagneaux L; Breuker C
J Patient Saf; 2021 Dec; 17(8):e1507-e1513. PubMed ID: 30365407
[TBL] [Abstract][Full Text] [Related]
28. Economic and safety benefits of pharmaceutical interventions by community and hospital pharmacists in Japan.
Tasaka Y; Yasunaga D; Tanaka M; Tanaka A; Asakawa T; Horio I; Miyauchi Y; Araki H
Int J Clin Pharm; 2016 Apr; 38(2):321-9. PubMed ID: 26744362
[TBL] [Abstract][Full Text] [Related]
29. Cost-outcome description of clinical pharmacist interventions in a university teaching hospital.
Gallagher J; Byrne S; Woods N; Lynch D; McCarthy S
BMC Health Serv Res; 2014 Apr; 14():177. PubMed ID: 24742158
[TBL] [Abstract][Full Text] [Related]
30. Economic cost-benefit analysis of person-centred medicines reviews by general practice pharmacists.
O'Mahony C; Dalton K; O'Hagan L; Murphy KD; Kinahan C; Coyle E; Sahm LJ; Byrne S; Kirke C
Int J Clin Pharm; 2024 May; ():. PubMed ID: 38814513
[TBL] [Abstract][Full Text] [Related]
31. Economic Outcomes Associated with a Pharmacist-Adjudicated Formulary Consult Service in a Veterans Affairs Medical Center.
Britt RB; Hashem MG; Bryan WE; Kothapalli R; Brown JN
J Manag Care Spec Pharm; 2016 Sep; 22(9):1051-61. PubMed ID: 27579827
[TBL] [Abstract][Full Text] [Related]
32. Epidemiology and cost analysis of pharmacist interventions at Ghent University Hospital.
Claus BO; Vandeputte FM; Robays H
Int J Clin Pharm; 2012 Oct; 34(5):773-8. PubMed ID: 22810891
[TBL] [Abstract][Full Text] [Related]
33. The cost-saving effect and prevention of medication errors by clinical pharmacist intervention in a nephrology unit.
Chen CC; Hsiao FY; Shen LJ; Wu CC
Medicine (Baltimore); 2017 Aug; 96(34):e7883. PubMed ID: 28834903
[TBL] [Abstract][Full Text] [Related]
34. Medication therapy management: 10 years of experience in a large integrated health care system.
Ramalho de Oliveira D; Brummel AR; Miller DB
J Manag Care Pharm; 2010 Apr; 16(3):185-95. PubMed ID: 20331323
[TBL] [Abstract][Full Text] [Related]
35. Clinical benefits and economic impact of post-surgical care provided by pharmacists in a Canadian hospital.
Neville HL; Chevalier B; Daley C; Nodwell L; Harding C; Hiltz A; MacDonald T; Skedgel C; MacKinnon NJ; Slayter K
Int J Pharm Pract; 2014 Jun; 22(3):216-22. PubMed ID: 23952872
[TBL] [Abstract][Full Text] [Related]
36. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist.
Kopp BJ; Mrsan M; Erstad BL; Duby JJ
Am J Health Syst Pharm; 2007 Dec; 64(23):2483-7. PubMed ID: 18029956
[TBL] [Abstract][Full Text] [Related]
37. Impact of pharmacist recommendations on the cost of drug therapy in ICU patients at a Malaysian hospital.
Zaidi ST; Hassan Y; Postma MJ; Ng SH
Pharm World Sci; 2003 Dec; 25(6):299-302. PubMed ID: 14689820
[TBL] [Abstract][Full Text] [Related]
38. Cost benefit analysis of clinical pharmacist interventions in medical intensive care unit in Palestine medical complex: Prospective interventional study.
Houso A; Hamdan M; Falana H
Saudi Pharm J; 2022 Dec; 30(12):1718-1724. PubMed ID: 36601501
[TBL] [Abstract][Full Text] [Related]
39. Proposed guidance on cost-avoidance studies in pharmacy practice.
Patanwala AE; Narayan SW; Haas CE; Abraham I; Sanders A; Erstad BL
Am J Health Syst Pharm; 2021 Aug; 78(17):1559-1567. PubMed ID: 34007979
[TBL] [Abstract][Full Text] [Related]
40. Impact of oral chemotherapy pharmacists on cost avoidance of oral oncolytics in an integrated health system.
Nguyen AL
J Oncol Pharm Pract; 2023 Sep; 29(6):1369-1373. PubMed ID: 36002947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
